JP2014517694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517694A5 JP2014517694A5 JP2014512189A JP2014512189A JP2014517694A5 JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5 JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014512189 A JP2014512189 A JP 2014512189A JP 2014517694 A5 JP2014517694 A5 JP 2014517694A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- acid sequence
- vector
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490450P | 2011-05-26 | 2011-05-26 | |
| US61/490,450 | 2011-05-26 | ||
| PCT/US2012/039897 WO2012162705A2 (en) | 2011-05-26 | 2012-05-29 | Cell and gene based methods to improve cardiac function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517694A JP2014517694A (ja) | 2014-07-24 |
| JP2014517694A5 true JP2014517694A5 (enExample) | 2015-07-16 |
| JP6162104B2 JP6162104B2 (ja) | 2017-07-12 |
Family
ID=47218136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512189A Active JP6162104B2 (ja) | 2011-05-26 | 2012-05-29 | 細胞及び遺伝子に基づく心臓機能改善方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9868937B2 (enExample) |
| EP (1) | EP2714709B1 (enExample) |
| JP (1) | JP6162104B2 (enExample) |
| KR (1) | KR20140035967A (enExample) |
| CN (1) | CN103946230B (enExample) |
| AU (1) | AU2012258525B2 (enExample) |
| BR (1) | BR112013030209A2 (enExample) |
| CA (1) | CA2837322C (enExample) |
| RU (1) | RU2608957C2 (enExample) |
| WO (1) | WO2012162705A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2837322C (en) | 2011-05-26 | 2023-03-21 | University Of Washington | Cell and gene based methods to improve cardiac function |
| EP2792742A1 (en) | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
| WO2015153357A1 (en) * | 2014-03-29 | 2015-10-08 | Beat Biotherapeutics Corp. | Compositions and methods for improving cardiac function |
| WO2016115543A2 (en) * | 2015-01-16 | 2016-07-21 | University Of Washington | Novel micro-dystrophins and related methods of use |
| CA2979229A1 (en) | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rp2 vectors for treating x-linked retinitis pigmentosa |
| EP3337892A2 (en) | 2015-08-18 | 2018-06-27 | Boston Scientific Scimed Inc. | Methods for producing cardiomyocyte cells |
| JP6940920B2 (ja) | 2017-02-04 | 2021-09-29 | アナバイオス コーポレーション | 医薬誘発性の変力作用および不整脈誘発のリスクを予測するためのシステムおよび方法 |
| CN108913655B (zh) * | 2018-07-16 | 2022-07-15 | 浙江大学 | 基于多能干细胞技术建立“人源性”心肌肥大模型的方法 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| KR20210102870A (ko) | 2018-08-30 | 2021-08-20 | 테나야 테라퓨틱스, 인코포레이티드 | 미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍 |
| US20200405824A1 (en) * | 2019-06-26 | 2020-12-31 | University Of Washington | Use of ribonucleotide reductase alone or in combination with micro-dystrophin to treat duchenne muscular dystrophy striated muscle disease |
| CN110384800B (zh) * | 2019-07-19 | 2021-06-08 | 广东省实验动物监测所 | LncRNA XLOC_075168在制备促进血管新生的药物中的应用 |
| FI4103214T3 (fi) | 2020-02-13 | 2026-07-03 | Tenaya Therapeutics Inc | Geeniterapian vektorit sydänsairauden hoitoon |
| US20240189481A1 (en) * | 2021-04-06 | 2024-06-13 | University Of Washington | Non-contractile cardiomyocytes for cardiac repair |
| CA3240616A1 (en) * | 2021-12-10 | 2023-06-15 | Christopher Dean HERZOG | Troponin c (tnnc1) gene therapy using aav vector |
| WO2025207745A1 (en) * | 2024-03-27 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of inducing dilated cardiomyopathy phenotype in cardiomyocytes and applications thereof |
| CN120758566B (zh) * | 2025-09-10 | 2025-11-21 | 瓯江实验室 | 一种在心肌细胞中特异性过表达zer1的病毒载体的构建及在心衰治疗中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02240440A (ja) | 1989-03-14 | 1990-09-25 | Shiigeru:Kk | 慣性ダンパ |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| US6151525A (en) | 1997-11-07 | 2000-11-21 | Medtronic, Inc. | Method and system for myocardial identifier repair |
| EP1085910A2 (en) | 1998-05-30 | 2001-03-28 | Collateral Therapeutics, Inc. | Methods of altering cardiac cell phenotype |
| CN1159445C (zh) | 1998-09-11 | 2004-07-28 | 加利福尼亚大学董事会 | 能在心脏中组织特异性表达的重组腺病毒 |
| EP1139751A4 (en) * | 1998-12-28 | 2003-03-19 | Arch Dev Corp | EFFICIENT AND STABLE -I (IN VIVO) GENE TRANSFER TO CARDIOMYCETS USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS |
| AU2002230999A1 (en) | 2000-12-21 | 2002-07-01 | Medtronic, Inc. | Electrically responsive promoter system |
| EP1509252A4 (en) * | 2002-05-08 | 2006-08-16 | Univ California | METHOD AND COMPOSITIONS FOR CORRECTING HEART TRANSFER FAULTS |
| WO2004024867A2 (en) | 2002-09-11 | 2004-03-25 | University Of Florida | Vigilant vector system |
| EP1654365A1 (en) | 2003-08-11 | 2006-05-10 | University Of South Florida | Vigilant cells |
| BRPI0416732A (pt) | 2003-11-21 | 2007-01-16 | Daiichi Asubio Pharma Co Ltd | métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito |
| US20050260637A1 (en) | 2004-03-25 | 2005-11-24 | Yun Yen | Drug screening |
| DE102011018586A1 (de) | 2011-04-26 | 2012-10-31 | Oliver Müller | Vektorsystem zur spezifischen Genexpression im Herzmuskel |
| CA2837322C (en) | 2011-05-26 | 2023-03-21 | University Of Washington | Cell and gene based methods to improve cardiac function |
-
2012
- 2012-05-29 CA CA2837322A patent/CA2837322C/en active Active
- 2012-05-29 BR BR112013030209A patent/BR112013030209A2/pt not_active Application Discontinuation
- 2012-05-29 KR KR1020137034630A patent/KR20140035967A/ko not_active Ceased
- 2012-05-29 WO PCT/US2012/039897 patent/WO2012162705A2/en not_active Ceased
- 2012-05-29 CN CN201280034527.5A patent/CN103946230B/zh not_active Expired - Fee Related
- 2012-05-29 EP EP12790042.1A patent/EP2714709B1/en active Active
- 2012-05-29 US US14/122,226 patent/US9868937B2/en active Active
- 2012-05-29 RU RU2013157590A patent/RU2608957C2/ru not_active IP Right Cessation
- 2012-05-29 JP JP2014512189A patent/JP6162104B2/ja active Active
- 2012-05-29 AU AU2012258525A patent/AU2012258525B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| JP2019513393A5 (enExample) | ||
| AR129651A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos | |
| JP2017538401A5 (enExample) | ||
| PH12020551744A1 (en) | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| JP2021536244A5 (enExample) | ||
| JP2019513399A5 (enExample) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| MY199445A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| BR112021018776A2 (pt) | Vetores de vírus adenoassociado recombinante | |
| JP2018520997A5 (enExample) | ||
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| JP2017048194A5 (enExample) | ||
| JP2015500002A5 (enExample) | ||
| MX2014009975A (es) | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. | |
| EA201492048A1 (ru) | Полипептиды, связывающиеся с хемокиновым рецептором | |
| JP2013501816A5 (enExample) | ||
| JP2018515096A5 (enExample) | ||
| FI3581650T3 (fi) | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi | |
| JP2015526391A5 (enExample) | ||
| JP2019523648A5 (enExample) | ||
| WO2015081101A8 (en) | Adeno-associated virus vectors for treatment of glycogen storage disease | |
| EA202092589A2 (ru) | Cxcr2-связывающие полипептиды | |
| HK1202434A1 (en) | Virus vectors for highly efficient transgene delivery |